← Leaderboards
Yingxian Xiao
Georgetown University
$1,605,749
Attributed
$1,605,749
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $547.5K · FY2010–14$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$1,605,749 · 2
By mechanism
U19$1,362,393 · 1
R21$243,356 · 1
Top collaborators
No co-investigators on record.
Most similar at Georgetown University
Same institution · by research overlap
- Kenneth J Kellar$5,397,634
- Kathryn L Sandberg$21,619,723
- Martha I Garcia-Davila$1,782,144
- Alan Paul Kozikowski$7,525,629
- Richard Alan Gillis$3,176,563
Others in their field
Top investigators on “Patch Clamp”
- Keith W Miller · Massachusetts General Hospital$23,700,247
- Ed Lein · Allen Institute$20,674,860
- Jonathan H Jaggar · University Of Tennessee Health Sci Ctr$19,557,463
- Henrique Prado Von Gersdorff · Oregon Health And Science University$16,378,938
- Anthony N Van Den Pol · Yale University$15,985,675
- Z Jimmy Zhou · University Of Arkansas Med Scis Ltl Rock$15,464,538
Research focus
Patch ClampSmokingMeasurementNicotinic ReceptorsPropertyReceptor DensityDrosophila Acetylcholine Receptor Alpha-SubunitLigandsNicotineNicotine DependencePhysiologicalPlayCigarette SmokingReceptorAgonistDesignDrug DiscoveryGated Ion ChannelMediatingNeuronsBinding (Molecular Function)BrainPathologic ProcessesSmoking Cessation
Grant awards (6)
Selective alpha4beta2 nAChR Desensitizers: in vitro Pharmacological Properties$298,198
U19 · FY2014 · DA · contact PI
Selective alpha4beta2 nAChR Desensitizers: in vitro Pharmacological Properties$297,743
U19 · FY2013 · DA · contact PI
Selective alpha4beta2 nAChR Desensitizers: in vitro Pharmacological Properties$302,444
U19 · FY2012 · DA · contact PI
Selective alpha4beta2 nAChR Desensitizers: in vitro Pharmacological Properties$304,158
U19 · FY2011 · DA · contact PI
High Throughput Screening for nAChRs: Cell Lines and Assay Development$243,356
R21 · FY2011 · DA · contact PI
Selective alpha4beta2 nAChR Desensitizers: in vitro Pharmacological Properties$159,850
U19 · FY2010 · DA · contact PI